NewsSource: EClinCloud Official Website Archive

Highlights | EClinCloud Showcases AI Innovations at the 2025 DIA Conference

1 min readEClinCloud Editorial Team
Highlights | EClinCloud at the 2025 DIA Conference, Showcasing AI Innovation (archived article cover)

From May 22 to 25, the 2025 DIA Drug Information Conference and Exhibition was successfully held at Shanghai Zhangjiang Science Hall. Bringing together leading forces in global drug innovation, the conference featured EClinCloud, a technology company focused on AI-enabled end-to-end clinical research, presenting the strengths of its integrated cloud platform and its AI innovations.

 

An Eye-Catching Booth Showcasing the Appeal of AI

During the exhibition, EClinCloud's tech-forward, professional booth design and wide range of AI application demonstrations drew considerable attention, with visitor traffic steadily growing. The interactive zone at the EClinCloud booth also featured a raffle with giveaways, keeping engagement high throughout the event.

Attendees expressed strong recognition of EClinCloud's brand strength. Many conference guests and industry peers stopped by to exchange views, engaging in in-depth discussions on EClinCloud's product strengths and AI technology innovation, with collaboration interest steadily emerging.

2025 DIA大会一临云展览现场  

 

 

Exchanging Ideas: Decoding New Pathways for AI-Enabled RBQM

During the May 24 sub-forum "Risk-Based Full-Lifecycle Data Quality Management," Dr. Qin Long, Founder & CEO of EClinCloud, held a lively discussion with attendees on "Application Practices and Challenges of Computerized Systems or AI-Supported/Assisted RBQM" and shared explorations and perspectives on integrating AI with RBQM, drawing broad attention and positive feedback from the audience.

2025 DIA大会演讲、圆桌讨论与合影  

The 2025 DIA China Annual Meeting has concluded successfully. EClinCloud gathered with new and longtime friends, not only demonstrating how AI technology deeply empowers clinical R&D, but also gaining greater shared perspective and collaboration opportunities through our discussions. We look forward to seeing you again!